On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Sangamo Biosciences, (NASDAQ:SGMO), Knowles (NYSE:KN), OXiGENE (NASDAQ:OXGN), VirnetX Holding (NYSEMKT:VHC)
Sangamo Biosciences, Inc. (NASDAQ:SGMO) decreased -4.91%, and closed at $17.63. The company holds the market capitalization of $1.22 B. For the last twelve months, the stock was able to keep return on equity at -12.40%, while return on assets at –10.60%, in response to its return on investment at -13.00%. Its 20-day moving average gained 2.31%, below 50-day moving average of 14.40%, above 200-day moving average of 29.43% from the latest market price of $17.63. The mean recommendation of analysts for this stock is 1.60. (Where 1=Buy, 5=Sale).
Sangamo Biosciences, Inc. (SGMO) a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States.
Knowles Corp (NYSE:KN) shares picked down -4.85%, and closed at $19.99. The stock volatility for the week is 4.05%, while for the month remained 3.57%. The company holds consensus target price of $24.11.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -1.02 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -182.30% and Annual EPS growth for the past 5 years is considered as 0.00%.
The mean recommendation of analysts for this stock is 2.30. (Where 1=Buy, 5=Sale).
Knowles Corp (KN) manufactures, and sells products and components to the mobile communications, consumer electronics, medical technology, telecommunications infrastructure, military, aerospace, and industrial markets worldwide. The company operates in two segments, Mobile Consumer Electronics and Specialty Components.
OXiGENE Inc (NASDAQ:OXGN) declined -4.85%, and closed at $1.57. The company has the market capitalization of $32.51 Million. The beta value of the stock is 2.07. On the other hand the stock’s volatility for the week is 6.83%, and for the month is 6.34%. The stock’s price to book ratio is $1.12. Analyst’s mean recommendation regarding this stock is 2.00. (Where 1=Buy, 5=Sale).
OXiGENE Inc (NASDAQ:OXGN) a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression.
VirnetX Holding Corporation (NYSEMKT:VHC) fell -4.81%, and closed at $6.14. The stock has the beta value of 1.74, and its volatility for the week is 6.91%, while for the month it is 7.84%. The company has the market capitalization of $319.26 million. The company holds the book value per share of 0.63, whereas cash per share is 0.79. Price to book ratio remained 9.75, while price to sale ratio is 266.07. Analysts mean recommendation for the stock is said to be 2.70 (where 1=Buy, 5=sale).
VirnetX Holding Corporation (VHC) develops software and technology solutions for securing real-time communications over the Internet. The companys software and technology solutions include secure domain name registry and GABRIEL Connection Technology that are designed to secure various real-time communications over the Internet, as well as enable organizations and individuals to establish communities of secure, registered users, and transmit information between various devices, networks, and operating systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
